Six Washington University in St. Louis research teams have been selected to receive funding as part of the Spring 2018 cycle of the Leadership in Entrepreneurial Acceleration Program, better known as the LEAP Inventor Challenge (LEAP).
LEAP exists to propel Washington University intellectual property towards commercialization. The competition supports all Washington University faculty, postdoc, staff and graduate student teams. Finalists are selected based on feedback from domain experts. They receive funding to help progress their early stage research from concepts and ideas to viable products and services.
Drug therapy for alpha-1-antitrypsin deficiency (ATD)
Repurposing drug combinations for treatment of alpha-1-antitrypsin deficiency (ATD) – the most common genetic cause of pediatric liver disease.
- Stephen C. Pak, PhD, Associate Professor of Pediatrics, Division of Newborn Medicine